Treatment(s) already received-Bone marrow transplant-Autologous Posts on Medivizor
Navigation Menu

Treatment(s) already received-Bone marrow transplant-Autologous Posts on Medivizor

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Evaluating the effectiveness and safety of adding ixazomib to lenalidomide maintenance therapy in patients with newly diagnosed multiple myeloma after ASCT.

Posted by on Apr 10, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (MM). The data showed that the addition of ixazomib to lenalidomide maintenance improved survival without cancer...

Read More

Bortezomib plus lenalidomide for patients with multiple myeloma a after stem cell transplant

Bortezomib plus lenalidomide for patients with multiple myeloma a after stem cell transplant

Posted by on Mar 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of bortezomib (Velcade) and lenalidomide (Revlimid) for patients with multiple myeloma after stem cell transplantation. This study found this combination is effective for these patients, with few side effects. Some background Multiple myeloma (MM) is a type of cancer...

Read More

Is stem cell transplant more effective than other treatments for multiple myeloma?

Is stem cell transplant more effective than other treatments for multiple myeloma?

Posted by on Feb 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effects of stem cell transplant to other newer treatments for recently diagnosed multiple myeloma (MM). The main finding was patients who received stem cell transplant had better outcomes than those who did not. Some background Stem cell transplant involves the transfer of cells to a patient. This is an effective...

Read More

Minimal residual disease and its association with transplant success in Multiple Myeloma.

Minimal residual disease and its association with transplant success in Multiple Myeloma.

Posted by on Jan 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study monitored the development of minimal residual disease (MRD) after transplant for multiple myeloma (MM). The main finding was that different patterns of MRD development are associated with varying success after stem cell transplant for MM. Some background There are many treatments for MM. Patients are often cured fully by...

Read More

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Posted by on Sep 4, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...

Read More

Outcomes from early relapse in multiple myeloma

Outcomes from early relapse in multiple myeloma

Posted by on Dec 22, 2017 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the effect of early relapse on survival in patients with multiple myeloma. Patients who had an early relapse had a worse overall survival than patients who did not have an early relapse.  Some background Despite advances in treatment, many patients with multiple myeloma will experience a relapse (have a return...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor